<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03197909</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL17_0210</org_study_id>
    <nct_id>NCT03197909</nct_id>
  </id_info>
  <brief_title>Involvement of Plasmatic Factors in the Peripheral Muscle Dysfunction of COPD Patients - In Vitro Study</brief_title>
  <official_title>Involvement of Plasmatic Factors in the Peripheral Muscle Dysfunction of COPD Patients - In Vitro Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic Obstructive Pulmonary Patients is a defined by persistent airflow limitation that is&#xD;
      usually progressive and associated with an enhanced chronic inflammatory response in the&#xD;
      airways and the lung to noxious particles or gases. It is associated with an atrophy of the&#xD;
      skeletal muscle that impairs the patient's prognosis. The biological mechanisms of this&#xD;
      muscle atrophy have not been elucidated, and the &quot;spill-over theory&quot; has recently emerged.&#xD;
      Indeed, in COPD patients, the pulmonary inflammation is associated with a systemic low-grade&#xD;
      inflammation, and the increased pro-inflamatory molelcules in the blood - which constitute&#xD;
      the cellular micro-environement of the muscle fibre - could activate the mechanisms of the&#xD;
      cell atrophy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 6, 2017</start_date>
  <completion_date type="Actual">January 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Myotube diameter of in vitro cultured myotubes</measure>
    <time_frame>6 days</time_frame>
    <description>Myotube diameter of in vitro cultured myotubes from healthy subjects, exposed to the serum of healthy controls and COPD patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Expression and translation of markers of</measure>
    <time_frame>6 days</time_frame>
    <description>Expression and translation of markers of anabolic and catabolic pathways</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Level of pro-Inflamatory markers</measure>
    <time_frame>6 days</time_frame>
    <description>Level of pro-Inflamatory markers in the serum</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">18</enrollment>
  <condition>Chronic Obstructive Pulmonary</condition>
  <arm_group>
    <arm_group_label>Healthy subjects</arm_group_label>
    <description>Determination of pro-inflammatory plasma factors at Healthy subjects aged from 35 to 85 years old</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COPD patients</arm_group_label>
    <description>Determination of pro-inflammatory plasma factors at COPD patients aged from 35 to 85 years old</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Determination of pro-inflammatory plasma factors</intervention_name>
    <description>Determination of pro-inflammatory plasma factors at COPD patients aged from 35 to 85 years old and Healthy subjects aged from 35 to 85 years old</description>
    <arm_group_label>COPD patients</arm_group_label>
    <arm_group_label>Healthy subjects</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Chronic Obstructive Pulmonary Patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        35 to 85 years old&#xD;
&#xD;
          -  COPD patients: association of symtoms (breathlessness, cough, sputum) and chronic&#xD;
             exposure to inhalated risk factors (like tobacco smoke) and a FEV1/VC ratio &lt;70%&#xD;
             assessed by a spirometry&#xD;
&#xD;
          -  Healthy subjects: A sedentariness assessed by a Voorrips score &lt;9.4 and/or a report of&#xD;
             &lt;150 min/week of moderate-to-vigorous physical activity&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A recent COPD exacerbation (&lt; 4weeks)&#xD;
&#xD;
          -  The decompensation of a comorbidity&#xD;
&#xD;
          -  An antioxidant supplementation or medication&#xD;
&#xD;
          -  A long-term systemic corticosteroid medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maurice HAYOT, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uhmontpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34290</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>June 21, 2017</study_first_submitted>
  <study_first_submitted_qc>June 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2017</study_first_posted>
  <last_update_submitted>April 17, 2019</last_update_submitted>
  <last_update_submitted_qc>April 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD (Chronic Obstructive Pulmonary Patients)</keyword>
  <keyword>Atrophy</keyword>
  <keyword>cell cultur</keyword>
  <keyword>systemic inflammation</keyword>
  <keyword>Catabolism</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

